SMMT250117P20000
- 2.85
- -1.05-26.92%
Summit Therapeutics Newsroom
JMP Securities Initiates Summit Therapeutics(SMMT.US) With Buy Rating, Announces Target Price $32
JMP Securities Initiates Coverage On Summit Therapeutics With Market Outperform Rating, Announces Price Target of $32
Stifel Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $40
Summit Therapeutics Analyst Ratings
H.C. Wainwright Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Cuts Target Price to $44
This Biotech Stock Could Rocket 800%, Analyst Says -- Barrons.com
Stifel Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $40
Summit Therapeutics Analyst Ratings
H.C. Wainwright Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $45
Buy Rating Affirmed for Summit Therapeutics Amid Promising Clinical Trials and Regulatory Progress
Citi Downgrades Summit Therapeutics(SMMT.US) to Hold Rating, Raises Target Price to $23
Citigroup Downgrades Summit Therapeutics to Neutral From Buy, Adjusts Price Target to $23 From $19
Summit Therapeutics Analyst Ratings
Stifel Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Raises Target Price to $40
Stifel Nicolaus Sticks to Its Buy Rating for Summit Therapeutics (SMMT)
H.C. Wainwright Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $45
Summit Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Summit Therapeutics Analyst Ratings
H.C. Wainwright Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Raises Target Price to $45
After the dual-antibody drug data from Summit Therapeutics (SMMT.US) defeated the "drug king", it was listed as Citigroup's preferred stock and the target price was raised.